The U.S. Food and Drug Administration (FDA) approved a supplemental efficacy application for Keytruda (pembrolizumab) on March 14, 2017. This approval, identified as BLA 125514 S-15, signifies new or expanded evidence of the drug's effectiveness, leading to an update in its approved uses.
Background
Pembrolizumab, marketed as Keytruda, is a well-established immunotherapy. Supplemental applications for existing drugs like Keytruda are typically submitted to the FDA when new clinical data supports an expansion of the drug's approved indications, a new patient population, or an update to its efficacy profile for an already approved use. These applications require rigorous review of new clinical trial data demonstrating the drug's safety and effectiveness for the proposed change.
What this means
This supplemental efficacy approval for Keytruda (pembrolizumab) means that the FDA has reviewed and accepted new data demonstrating the drug's effectiveness for an additional use or patient group. For clinicians, this likely translates to an updated prescribing information, offering new treatment options for patients. Researchers will find the underlying data for this approval relevant for understanding the evolving landscape of immunotherapy, while patient advocates can highlight these expanded uses to inform eligible patients about new therapeutic possibilities.
Source
The information regarding this supplemental efficacy approval was sourced from the U.S. Food and Drug Administration (FDA). The approval for BLA 125514 S-15 was granted on March 14, 2017, and details are available on accessdata.fda.gov.